08 July 2014
Russia is expecting to have its own therapeutic vaccine to fight HIV in three-to-four years, following a series of clinical trials. Andrei Kozlov of the Federal Medical and Biological Agency, an official overseeing the vaccine project, shared the news with the Russian news agency RIA Novosti.
The new drug candidate is being designed to help trigger immune response to fight the deadly virus in patients who are already HIV-positive. The vaccine is believed to be able to cure the disease or at least slow down its progress considerably. The yet-unspecified developers claim their solution will help cut the cost of treatment as it will be “much less expensive” compared to existing drugs.
A lengthy series of preclinical trials took almost 15 years to complete. Now, in a clinical trial phase that will last several months, a reported 60 HIV-positive volunteers will be grouped in three different teams, some receiving a placebo while others having the new vaccine administered in combination with anti-retrovirus therapies.
Experts currently talk about three different HIV vaccines being developed in Russia. However, only one of the three appears to have its advanced testing stage funded from federal coffers (a reported $1.5m). Where this winning group of developers is located has yet to be specified.
Merry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
The first Russian device for testing TB is registered
14 January 2025
Russians spend 1.6 trillion rubles on medications in 2024
14 January 2025
2024 drug approvals: Small companies loom large with several key FDA nods
13 January 2025
Special Regulations for Foreign-Packaged Medicines Extended Until the End of 2025
13 January 2025